5 Citations (Scopus)

Abstract

Polyomaviruses (PyVs) silently infect most humans, but they can cause life-threatening diseases in immunocompromised individuals. The JC polyomavirus (JCPyV) induces progressive multifocal leukoencephalopathy, a severe demyelinating disease in multiple sclerosis patients receiving immunomodulatory therapy, and BK polyomavirus (BKPyV)-associated nephropathy is a major cause of kidney allograft failure. No effective anti-PyV agents are available. Several compounds have been reported to possess anti-PyV activity in vitro, but none have shown efficacy in clinical trials. Productive PyV infection involves usurping the cellular retrograde vesicular transport pathway to enable endocytosed virions to navigate to the endoplasmic reticulum where virion uncoating begins. Compounds inhibiting this pathway have been shown to reduce infection by simian virus 40 (SV40), JCPyV, and BKPyV in tissue culture. In this study, we investigated the potential of Retro-2.1, a retrograde transport inhibitor, to limit infection by mouse polyomavirus (MuPyV) in vivo. We found that Retro-2.1 significantly reduced MuPyV levels in the kidney during acute infection without affecting renal function or the MuPyV-specific CD8 T cell response. To approximate the clinical setting of PyV resurgence in immunocompromised hosts, we showed that antibody-mediated depletion of T cells in persistently infected mice elevated MuPyV levels in the kidney and that Retro-2.1 blunted this increase in virus levels. In summary, these data indicate that inhibition of retrograde vesicular transport in vivo controls infection in a natural PyV mouse model and supports development of these compounds as potential therapeutic agents for individuals at risk for human PyV-associated diseases.

Original languageEnglish (US)
Article numbere00494-17
JournalmSphere
Volume2
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Polyomavirus Infections
Polyomavirus
BK Virus
JC Virus
Kidney
Virion
Infection
Progressive Multifocal Leukoencephalopathy
T-Lymphocytes
Simian virus 40
Immunomodulation
Immunocompromised Host
Demyelinating Diseases
Infection Control
Endocytosis
Endoplasmic Reticulum
Multiple Sclerosis
Renal Insufficiency
Allografts
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Molecular Biology

Cite this

Maru, Saumya ; Jin, Ge ; Desai, Dhimant ; Amin, Shantu ; Shwetank ; Lauver, Matthew D. ; Lukacher, Aron. / Inhibition of retrograde transport limits polyomavirus infection in vivo. In: mSphere. 2017 ; Vol. 2, No. 6.
@article{b8035c3e64c8421295eb388ad8104089,
title = "Inhibition of retrograde transport limits polyomavirus infection in vivo",
abstract = "Polyomaviruses (PyVs) silently infect most humans, but they can cause life-threatening diseases in immunocompromised individuals. The JC polyomavirus (JCPyV) induces progressive multifocal leukoencephalopathy, a severe demyelinating disease in multiple sclerosis patients receiving immunomodulatory therapy, and BK polyomavirus (BKPyV)-associated nephropathy is a major cause of kidney allograft failure. No effective anti-PyV agents are available. Several compounds have been reported to possess anti-PyV activity in vitro, but none have shown efficacy in clinical trials. Productive PyV infection involves usurping the cellular retrograde vesicular transport pathway to enable endocytosed virions to navigate to the endoplasmic reticulum where virion uncoating begins. Compounds inhibiting this pathway have been shown to reduce infection by simian virus 40 (SV40), JCPyV, and BKPyV in tissue culture. In this study, we investigated the potential of Retro-2.1, a retrograde transport inhibitor, to limit infection by mouse polyomavirus (MuPyV) in vivo. We found that Retro-2.1 significantly reduced MuPyV levels in the kidney during acute infection without affecting renal function or the MuPyV-specific CD8 T cell response. To approximate the clinical setting of PyV resurgence in immunocompromised hosts, we showed that antibody-mediated depletion of T cells in persistently infected mice elevated MuPyV levels in the kidney and that Retro-2.1 blunted this increase in virus levels. In summary, these data indicate that inhibition of retrograde vesicular transport in vivo controls infection in a natural PyV mouse model and supports development of these compounds as potential therapeutic agents for individuals at risk for human PyV-associated diseases.",
author = "Saumya Maru and Ge Jin and Dhimant Desai and Shantu Amin and Shwetank and Lauver, {Matthew D.} and Aron Lukacher",
year = "2017",
month = "11",
day = "1",
doi = "10.1128/mSphere.00494-17",
language = "English (US)",
volume = "2",
journal = "mSphere",
issn = "2379-5042",
publisher = "American Society for Microbiology",
number = "6",

}

Inhibition of retrograde transport limits polyomavirus infection in vivo. / Maru, Saumya; Jin, Ge; Desai, Dhimant; Amin, Shantu; Shwetank; Lauver, Matthew D.; Lukacher, Aron.

In: mSphere, Vol. 2, No. 6, e00494-17, 01.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of retrograde transport limits polyomavirus infection in vivo

AU - Maru, Saumya

AU - Jin, Ge

AU - Desai, Dhimant

AU - Amin, Shantu

AU - Shwetank,

AU - Lauver, Matthew D.

AU - Lukacher, Aron

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Polyomaviruses (PyVs) silently infect most humans, but they can cause life-threatening diseases in immunocompromised individuals. The JC polyomavirus (JCPyV) induces progressive multifocal leukoencephalopathy, a severe demyelinating disease in multiple sclerosis patients receiving immunomodulatory therapy, and BK polyomavirus (BKPyV)-associated nephropathy is a major cause of kidney allograft failure. No effective anti-PyV agents are available. Several compounds have been reported to possess anti-PyV activity in vitro, but none have shown efficacy in clinical trials. Productive PyV infection involves usurping the cellular retrograde vesicular transport pathway to enable endocytosed virions to navigate to the endoplasmic reticulum where virion uncoating begins. Compounds inhibiting this pathway have been shown to reduce infection by simian virus 40 (SV40), JCPyV, and BKPyV in tissue culture. In this study, we investigated the potential of Retro-2.1, a retrograde transport inhibitor, to limit infection by mouse polyomavirus (MuPyV) in vivo. We found that Retro-2.1 significantly reduced MuPyV levels in the kidney during acute infection without affecting renal function or the MuPyV-specific CD8 T cell response. To approximate the clinical setting of PyV resurgence in immunocompromised hosts, we showed that antibody-mediated depletion of T cells in persistently infected mice elevated MuPyV levels in the kidney and that Retro-2.1 blunted this increase in virus levels. In summary, these data indicate that inhibition of retrograde vesicular transport in vivo controls infection in a natural PyV mouse model and supports development of these compounds as potential therapeutic agents for individuals at risk for human PyV-associated diseases.

AB - Polyomaviruses (PyVs) silently infect most humans, but they can cause life-threatening diseases in immunocompromised individuals. The JC polyomavirus (JCPyV) induces progressive multifocal leukoencephalopathy, a severe demyelinating disease in multiple sclerosis patients receiving immunomodulatory therapy, and BK polyomavirus (BKPyV)-associated nephropathy is a major cause of kidney allograft failure. No effective anti-PyV agents are available. Several compounds have been reported to possess anti-PyV activity in vitro, but none have shown efficacy in clinical trials. Productive PyV infection involves usurping the cellular retrograde vesicular transport pathway to enable endocytosed virions to navigate to the endoplasmic reticulum where virion uncoating begins. Compounds inhibiting this pathway have been shown to reduce infection by simian virus 40 (SV40), JCPyV, and BKPyV in tissue culture. In this study, we investigated the potential of Retro-2.1, a retrograde transport inhibitor, to limit infection by mouse polyomavirus (MuPyV) in vivo. We found that Retro-2.1 significantly reduced MuPyV levels in the kidney during acute infection without affecting renal function or the MuPyV-specific CD8 T cell response. To approximate the clinical setting of PyV resurgence in immunocompromised hosts, we showed that antibody-mediated depletion of T cells in persistently infected mice elevated MuPyV levels in the kidney and that Retro-2.1 blunted this increase in virus levels. In summary, these data indicate that inhibition of retrograde vesicular transport in vivo controls infection in a natural PyV mouse model and supports development of these compounds as potential therapeutic agents for individuals at risk for human PyV-associated diseases.

UR - http://www.scopus.com/inward/record.url?scp=85041503013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041503013&partnerID=8YFLogxK

U2 - 10.1128/mSphere.00494-17

DO - 10.1128/mSphere.00494-17

M3 - Article

VL - 2

JO - mSphere

JF - mSphere

SN - 2379-5042

IS - 6

M1 - e00494-17

ER -